1. Ligand-based drug repurposing strategy identified SARS-CoV-2 RNA G-quadruplex binders
- Author
-
Federica Moraca, Simona Marzano, Francesco D'Amico, Antonio Lupia, Silvia Di Fonzo, Eleonora Vertecchi, Erica Salvati, Anna Di Porzio, Bruno Catalanotti, Antonio Randazzo, Bruno Pagano, Jussara Amato, Moraca, F., Marzano, S., D'Amico, F., Lupia, A., Di Fonzo, S., Vertecchi, E., Salvati, E., Di Porzio, A., Catalanotti, B., Randazzo, A., Pagano, B., and Amato, J.
- Subjects
G-quadruplex ,SARS-CoV-2 ,Drug Repositioning ,Metals and Alloys ,RNA G-quadruplex ,DNA ,General Chemistry ,Ligands ,Antiviral Agents ,Catalysis ,COVID-19 Drug Treatment ,Surfaces, Coatings and Films ,Electronic, Optical and Magnetic Materials ,Molecular Docking Simulation ,G-Quadruplexes ,Antiviral Agents, COVID-19, Drug Repositioning, Ligands, Molecular Docking Simulation, RNA, SARS-CoV-2 ,Materials Chemistry ,Ceramics and Composites ,Humans ,RNA, Viral - Abstract
The single-stranded RNA genome of SARS-CoV-2 contains some G-quadruplex-forming G-rich elements which are putative drug targets. Here, we performed a ligand-based pharmacophore virtual screening of FDA approved drugs to find candidates targeting such RNA structures. Further in silico and in vitro assays identified three drugs as emerging SARS-CoV-2 RNA G-quadruplex binders.
- Published
- 2022
- Full Text
- View/download PDF